These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 36414626)

  • 1. Effectiveness of KarXT (xanomeline-trospium) for cognitive impairment in schizophrenia: post hoc analyses from a randomised, double-blind, placebo-controlled phase 2 study.
    Sauder C; Allen LA; Baker E; Miller AC; Paul SM; Brannan SK
    Transl Psychiatry; 2022 Nov; 12(1):491. PubMed ID: 36414626
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline-trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial.
    Kaul I; Sawchak S; Correll CU; Kakar R; Breier A; Zhu H; Miller AC; Paul SM; Brannan SK
    Lancet; 2024 Jan; 403(10422):160-170. PubMed ID: 38104575
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antipsychotic Efficacy of KarXT (Xanomeline-Trospium): Post Hoc Analysis of Positive and Negative Syndrome Scale Categorical Response Rates, Time Course of Response, and Symptom Domains of Response in a Phase 2 Study.
    Weiden PJ; Breier A; Kavanagh S; Miller AC; Brannan SK; Paul SM
    J Clin Psychiatry; 2022 May; 83(3):. PubMed ID: 35552528
    [No Abstract]   [Full Text] [Related]  

  • 4. Safety and tolerability of KarXT (xanomeline-trospium) in a phase 2, randomized, double-blind, placebo-controlled study in patients with schizophrenia.
    Correll CU; Angelov AS; Miller AC; Weiden PJ; Brannan SK
    Schizophrenia (Heidelb); 2022 Dec; 8(1):109. PubMed ID: 36463237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of Xanomeline-Trospium Chloride in Schizophrenia: A Randomized Clinical Trial.
    Kaul I; Sawchak S; Walling DP; Tamminga CA; Breier A; Zhu H; Miller AC; Paul SM; Brannan SK
    JAMA Psychiatry; 2024 Aug; 81(8):749-756. PubMed ID: 38691387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current Findings and Potential Mechanisms of KarXT (Xanomeline-Trospium) in Schizophrenia Treatment.
    Azargoonjahromi A
    Clin Drug Investig; 2024 Jul; 44(7):471-493. PubMed ID: 38904739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evidence of trospium's ability to mitigate cholinergic adverse events related to xanomeline: phase 1 study results.
    Breier A; Brannan SK; Paul SM; Miller AC
    Psychopharmacology (Berl); 2023 May; 240(5):1191-1198. PubMed ID: 37036495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Muscarinic Cholinergic Receptor Agonist and Peripheral Antagonist for Schizophrenia.
    Brannan SK; Sawchak S; Miller AC; Lieberman JA; Paul SM; Breier A
    N Engl J Med; 2021 Feb; 384(8):717-726. PubMed ID: 33626254
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia.
    Shekhar A; Potter WZ; Lightfoot J; Lienemann J; Dubé S; Mallinckrodt C; Bymaster FP; McKinzie DL; Felder CC
    Am J Psychiatry; 2008 Aug; 165(8):1033-9. PubMed ID: 18593778
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of KarXT on negative symptoms in acute schizophrenia: A post hoc analysis of pooled data from 3 trials.
    Horan WP; Targum SD; Claxton A; Kaul I; Yohn SE; Marder SR; Miller AC; Brannan SK
    Schizophr Res; 2024 Dec; 274():57-65. PubMed ID: 39260339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy, safety, and tolerability of xanomeline for schizophrenia spectrum disorders: a systematic review.
    Leber A; Ramachandra R; Ceban F; Kwan ATH; Rhee TG; Wu J; Cao B; Jawad MY; Teopiz KM; Ho R; Le GH; Ramachandra D; McIntyre RS
    Expert Opin Pharmacother; 2024 Mar; 25(4):467-476. PubMed ID: 38515004
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of the novel glycine transporter inhibitor BI 425809 once daily in patients with schizophrenia: a double-blind, randomised, placebo-controlled phase 2 study.
    Fleischhacker WW; Podhorna J; Gröschl M; Hake S; Zhao Y; Huang S; Keefe RSE; Desch M; Brenner R; Walling DP; Mantero-Atienza E; Nakagome K; Pollentier S
    Lancet Psychiatry; 2021 Mar; 8(3):191-201. PubMed ID: 33610228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of the α7-Nicotinic Acetylcholine Receptor Agonist ABT-126 in the Treatment of Cognitive Impairment Associated With Schizophrenia: Results From a Phase 2b Randomized Controlled Study in Smokers.
    Haig GM; Wang D; Zhao J; Othman AA; Bain EE
    J Clin Psychiatry; 2018; 79(3):. PubMed ID: 28922590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the Efficacy, Safety, and Tolerability of BI 409306, a Novel Phosphodiesterase 9 Inhibitor, in Cognitive Impairment in Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled, Phase II Trial.
    Brown D; Nakagome K; Cordes J; Brenner R; Gründer G; Keefe RSE; Riesenberg R; Walling DP; Daniels K; Wang L; McGinniss J; Sand M
    Schizophr Bull; 2019 Mar; 45(2):350-359. PubMed ID: 29718385
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized, Double-Blind, Placebo-Controlled Study of Encenicline, an α7 Nicotinic Acetylcholine Receptor Agonist, as a Treatment for Cognitive Impairment in Schizophrenia.
    Keefe RS; Meltzer HA; Dgetluck N; Gawryl M; Koenig G; Moebius HJ; Lombardo I; Hilt DC
    Neuropsychopharmacology; 2015 Dec; 40(13):3053-60. PubMed ID: 26089183
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of xanomeline in Alzheimer disease: cognitive improvement measured using the Computerized Neuropsychological Test Battery (CNTB).
    Veroff AE; Bodick NC; Offen WW; Sramek JJ; Cutler NR
    Alzheimer Dis Assoc Disord; 1998 Dec; 12(4):304-12. PubMed ID: 9876958
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Site-independent confirmation of primary site-based PANSS ratings in a schizophrenia trial.
    Targum SD; Murphy C; Breier A; Brannan SK
    J Psychiatr Res; 2021 Dec; 144():241-246. PubMed ID: 34700212
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease.
    Bodick NC; Offen WW; Levey AI; Cutler NR; Gauthier SG; Satlin A; Shannon HE; Tollefson GD; Rasmussen K; Bymaster FP; Hurley DJ; Potter WZ; Paul SM
    Arch Neurol; 1997 Apr; 54(4):465-73. PubMed ID: 9109749
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cognitive Effects of MIN-101 in Patients With Schizophrenia and Negative Symptoms: Results From a Randomized Controlled Trial.
    Keefe RSE; Harvey PD; Khan A; Saoud JB; Staner C; Davidson M; Luthringer R
    J Clin Psychiatry; 2018; 79(3):. PubMed ID: 29873956
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of Cognition Support Formula® on cognitive function in older adults with subjective cognitive impairment: a protocol for a 26-week, randomised, double-blind, placebo-controlled trial.
    Cave AE; Chang DH; Münch GW; Steiner GZ
    Trials; 2019 Jun; 20(1):345. PubMed ID: 31182153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.